UPTEC startup selected for new European acceleration programme

BEAT Therapeutics, a startup incubated at UPTEC – Science and Technology Park of the University of Porto, was one of those chosen to take part in the acceleration programme of the Ready2Scale project, funded by the European Union.

Thanks to this six-month initiative, the startup will have access to €60,000 in financial support, as well as advice from mentors and experts in the sector, missions to discover new markets and networking events.

The work carried out by BEAT Therapeutics centres on the discovery and development of innovative therapies for the treatment of aggressive cancers. Focused on anti-cancer agents that act on DNA repair, the company aims to drive significant advances in cancer research: “our mission is to make new approaches available for indications with unmet medical needs, helping to significantly improve the survival and quality of life of cancer patients”, explains Ângela Carvalho, co-founder and CEO of BEAT Therapeutics.

The main drug candidate, currently in the pre-clinical development phase, is a molecule designed to inhibit DNA repair in cancer cells by interrupting a central pathway in homologous recombination. Throughout their participation in this programme, “the main objective is to accelerate the development of the (…) drug candidate, working with strategic partners to integrate new technologies that guarantee solid validation in line with future clinical development”, adds the CEO.

Beat Therapeutics: Ready2Scale acceleration programme

In addition to BEAT Therapeutics, nine other European companies have been selected for the Ready2Scale project programme, which aims to facilitate cross-border collaboration and support the growth of startups in the digital and deep tech sector in the European market.